Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
Alzheimer's disease
albumin
albutein
clinical trial
plasma exchange
plasmapheresis
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
02
07
2021
received:
12
03
2021
accepted:
11
08
2021
pubmed:
3
11
2021
medline:
20
7
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
We report the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality-of-life (QoL) outcomes in mild-to-moderate Alzheimer's disease (AD) patients in a phase 2b/3 trial (Alzheimer's Management by Albumin Replacement [AMBAR] study). Three hundred forty-seven patients were randomized into placebo (sham-PE) and three PE-treatment arms with low/high doses of albumin, with/without intravenous immunoglobulin (IVIG). Specific test measurements were performed at baseline; month 2 (weekly conventional PE); months 6, 9, and 12 (monthly low-volume PE [LVPE]); and month 14. The PE-treated mild-AD cohort improved their language fluency and processing speed versus placebo at month 14 (effect sizes: >100%; P-values: .03 to .001). The moderate-AD cohort significantly improved short-term verbal memory (effect sizes: 94% to >100%; P-values: .02 to .003). The progression of the neuropsychiatric symptoms of PE-treated was similar to placebo. Mild-AD patients showed improved QoL (P-values: .04 to .008). PE-treated AD patients showed improvement in memory, language abilities, processing speed, and QoL-AD. No worsening of their psychoaffective status was observed.
Identifiants
pubmed: 34726348
doi: 10.1002/alz.12477
pmc: PMC9540900
doi:
Substances chimiques
Albumins
0
Methacrylates
0
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1314-1324Informations de copyright
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Eur Neurol. 1994;34(5):277-82
pubmed: 7995303
Drug News Perspect. 2009 Jul-Aug;22(6):325-39
pubmed: 19771322
Front Aging Neurosci. 2017 Mar 10;9:46
pubmed: 28344552
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5
pubmed: 11438712
J Alzheimers Dis. 2014;38(4):753-65
pubmed: 24072068
Alzheimers Res Ther. 2017 Dec 8;9(1):95
pubmed: 29221491
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Alzheimers Dement. 2020 Oct;16(10):1412-1425
pubmed: 32715623
JAMA. 2018 Jan 9;319(2):130-142
pubmed: 29318278
Lancet. 1995 Dec 9;346(8989):1524-8
pubmed: 7491048
Alzheimer Dis Assoc Disord. 1994;8 Suppl 3:138-50
pubmed: 7999340
J Biol Chem. 1996 Dec 20;271(51):32916-22
pubmed: 8955133
N Engl J Med. 2018 May 3;378(18):1691-1703
pubmed: 29719179
J Alzheimers Dis. 2017;56(1):129-143
pubmed: 27911295
Am J Respir Crit Care Med. 2013 Sep 1;188(5):586-92
pubmed: 23848267
J Alzheimers Dis. 2009;16(2):325-9
pubmed: 19221422
Am J Geriatr Psychiatry. 2015 Dec;23(12):1280-1289
pubmed: 26560513
Brain Behav. 2017 Mar 06;7(4):e00661
pubmed: 28413709
Antioxid Redox Signal. 2012 Dec 1;17(11):1515-27
pubmed: 22587567
JAMA. 2004 Jan 21;291(3):317-24
pubmed: 14734594
J Neurol Neurosurg Psychiatry. 2003 Nov;74(11):1567-70
pubmed: 14617718
Ann Neurol. 1999 Dec;46(6):878-86
pubmed: 10589540
Alzheimers Dement (N Y). 2019 Jun 24;5:231-240
pubmed: 31297437
J Alzheimers Dis. 2018;63(4):1395-1404
pubmed: 29782326
Brain Behav Immun. 2012 Oct;26(7):1072-6
pubmed: 22749892
N Engl J Med. 2018 Jan 25;378(4):321-330
pubmed: 29365294
J Alzheimers Dis. 2014;40(3):643-57
pubmed: 24503620
Nat Med. 2014 Jun;20(6):659-63
pubmed: 24793238
J Clin Nurs. 2004 Sep;13(6B):105-10
pubmed: 15724825
N Engl J Med. 2014 Jan 23;370(4):311-21
pubmed: 24450890
Neurology. 1997 May;48(5 Suppl 6):S10-6
pubmed: 9153155
J Alzheimers Dis. 2018;61(1):321-332
pubmed: 29154283
J Am Geriatr Soc. 1992 Sep;40(9):922-35
pubmed: 1512391
N Engl J Med. 2019 Apr 11;380(15):1408-1420
pubmed: 30970186
Pharmacol Res Perspect. 2017 Oct;5(5):
pubmed: 28971614
Appl Neuropsychol Adult. 2018 Sep-Oct;25(5):448-457
pubmed: 28548549
Rev Neurol. 2003 Nov 16-30;37(10):917-26
pubmed: 14634919
J Alzheimers Dis. 2012;30(1):109-20
pubmed: 22406443
J Alzheimers Dis. 2012;29(1):159-70
pubmed: 22232005
Curr Alzheimer Res. 2019;16(2):156-165
pubmed: 30484408
N Engl J Med. 2014 Jan 23;370(4):322-33
pubmed: 24450891
Alzheimers Dement (N Y). 2019 Feb 26;5:61-69
pubmed: 30859122
Mol Psychiatry. 2020 Nov;25(11):2942-2951
pubmed: 30514930
Alzheimers Dement. 2022 Jul;18(7):1314-1324
pubmed: 34726348
Science. 2014 May 9;344(6184):630-4
pubmed: 24797482
J Alzheimers Dis. 2014;38(3):481-95
pubmed: 24002185